Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 31 - Medicinal preparations containing organic active ingredients
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
10/2010
10/26/2010CA2473931C Irrigation solution and methods for use
10/26/2010CA2457780C Topical compositions and methods for treating pain
10/26/2010CA2457053C Preventive agent/remedial agent for constipation predominant ibs
10/26/2010CA2449192C Novel nitriles useful as reversible inhibitors of cysteine proteases
10/26/2010CA2434608C Promoting cell regeneration and/or cell differentiation with non-metabolizable sugar and a polymeric absorbent
10/26/2010CA2422708C 4,5-dihydro-1h-pyrazole derivatives having cb1-antagonistic activity
10/26/2010CA2418921C Novel composition
10/26/2010CA2418316C Process for producing mouldings from (meth)acrylate copolymers by means of injection moulding
10/26/2010CA2418030C Isolation of glucan particles and uses thereof
10/26/2010CA2417190C New beta-amyloid inhibitors, processes for preparing them and their use as pharmaceutical compositions
10/26/2010CA2412164C Amidine derivatives as selective antagonists of nmda receptors
10/26/2010CA2410594C Heterocyclic aminoalkylpyridine derivatives as psychopharmaceuticals
10/26/2010CA2410201C Zoledronic acid or salts thereof for use in the treatment of conditions of abnormally increased bone turnover
10/26/2010CA2409221C Prophylactic and therapeutic treatment of infectious and other diseases with mono- and disaccharide-based compounds
10/26/2010CA2404641C Oral delivery method and composition for solid medications or dietary supplements
10/26/2010CA2400700C Antiviral azaindole derivatives
10/26/2010CA2398707C C1 inhibitor produced in the milk of transgenic mammals
10/26/2010CA2396956C Polypharmacophoric agents
10/26/2010CA2381229C Stabilized g-csf preparations
10/26/2010CA2372058C Hemisynthetic method of ecteinascidins and new intermediates
10/26/2010CA2337789C Formulations for controlling human lice
10/26/2010CA2327494C Novel crystalline forms of an antiviral benzimidazole compound
10/26/2010CA2326501C Binding molecules derived from immunoglobulins which do not trigger complement mediated lysis
10/26/2010CA2304700C Lipophilic diesters of chelating agents
10/26/2010CA2293436C Imidazolyl-cyclic acetals as tnf inhibitors
10/26/2010CA2192928C Benzoheterocyclic derivatives
10/26/2010CA2163111C Process for the preparation of an oral solid dosage form containing diclofenac
10/26/2010CA2135591C Stabilized oligonucleotides and their use
10/26/2010CA2133323C Self-assembling polynucleotide delivery system
10/21/2010WO2010121268A2 Regulation of aging by modulation of mitochondrial function
10/21/2010WO2010121243A1 Compounds, pharmaceutical compositions and methods of use of 2-aryl pyridylazoles
10/21/2010WO2010121232A1 Methods and compositions for treatment of ischemic conditions and conditions related to mitochondrial function
10/21/2010WO2010121226A2 Anticancer agents
10/21/2010WO2010121225A2 Method of treating disorders associated with protein kinase ck2 activity
10/21/2010WO2010121196A1 Methods of assessing activity of a polysaccharide composition
10/21/2010WO2010121177A2 Pharmaceutically active compositions comprising oxidative stress modulators (osm), new chemical entities, compositions and uses
10/21/2010WO2010121175A1 Combination targeted therapy for lung cancer
10/21/2010WO2010121162A1 Use of transforming growth factor-b receptor inhibitors to suppress ocular scarring
10/21/2010WO2010121133A2 Multimodal imaging of fibrin
10/21/2010WO2010121128A2 Compositions and methods for treating or inhibiting liver injury
10/21/2010WO2010121082A2 Emulsions of perfluorocarbons
10/21/2010WO2010121081A1 Mineral salt-sulfonic acid compositions and methods of use
10/21/2010WO2010121050A2 Sensor-based wireless communication systems using compressive sampling
10/21/2010WO2010121046A1 4-azetidinyl-1-phenyl-cyclohexane antagonists of ccr2
10/21/2010WO2010121036A1 4-azetidinyl-1-heteroatom linked-cyclohexane antagonists of ccr2
10/21/2010WO2010121022A1 Monoamine reuptake inhibitors
10/21/2010WO2010121014A1 Methods and compositions for treating type 2 diabetes and the metabolic syndrome
10/21/2010WO2010121011A1 4-azetidinyl-1-heteroaryl-cyclohexane antagonists of ccr2
10/21/2010WO2010120998A1 Pyrimidine compounds, their use as mtor kinase and pi3 kinase inhibitors, and their syntheses
10/21/2010WO2010120996A1 5,6,7,8-tetrahydropyrido[3,4-d]pyrimidine compounds, their use as mtor kinase and pi3 kinase inhibitors, and their syntheses
10/21/2010WO2010120991A1 5, 6, 7, 8-tetrahydropyrido[4,3-d]pyrimidine compounds, their use as mtor, pi3, and hsmg-1 kinase inhibitors, and their syntheses
10/21/2010WO2010120987A1 Ring fused, ureidoaryl- and carbamoylaryl-bridged morpholino-pyrimidine compounds, their use as mtor kinase and pi3 kinase inhibitors, and their syntheses
10/21/2010WO2010120980A1 Methods for inhibiting angiogenesis with multi-arm polymeric conjugates of 7-ethyl-10-hydroxycamptothecin
10/21/2010WO2010120969A1 Targeting of the mir-30 family and let-7 family as a treatment for heart disease
10/21/2010WO2010120963A1 Tablet formulation for p38 inhibitor and method
10/21/2010WO2010120935A1 Anti-viral compounds
10/21/2010WO2010120910A1 3-(phenoxypyrrolidin-3-yl-methyl)heteroaryl, 3-(phenylpyrrolidin-3-ylmethoxy)heteroaryl, and 3-(heteroarylpyrrolidin-3-ylmethoxy)heteroaryl compounds
10/21/2010WO2010120889A1 Treatment of metabolic syndrome with cyclic amides
10/21/2010WO2010120880A1 Treatment of liver diseases with a caspase inhibitor
10/21/2010WO2010120875A2 Treatment of skin damage
10/21/2010WO2010120872A2 Method of decreasing pro-adam10 secretase and/or beta secretase levels
10/21/2010WO2010120861A1 Methods of treating cancers with her3 antisense oligonucleotides
10/21/2010WO2010120841A1 Aqueous ophthalmic compositions containing anionic therapeutic agents
10/21/2010WO2010120797A2 Methods of reduction of interpatient variability
10/21/2010WO2010120755A1 Bioavailable capsule compositions of amorphous alpha-(n-sulfonamido)acetamide compound
10/21/2010WO2010120750A2 Amorphous esomeprazole magnesium
10/21/2010WO2010120741A1 Compositions and methods for modulating retinol binding to retinol binding protein 4 (rbp4)
10/21/2010WO2010120736A1 High fiber nutritional emulsions for blood glucose control
10/21/2010WO2010120719A1 Compositions and methods for the treatment of inflammation
10/21/2010WO2010120698A1 Vitamin d receptor agonists and uses thereof
10/21/2010WO2010120695A2 5-ht4 receptor agonist compounds for treatment of cognitive disorders
10/21/2010WO2010120682A1 Milk oligosaccharide compositions and use thereof in treating infection in animals
10/21/2010WO2010120661A1 Bleached dextrin and methods of forming the same
10/21/2010WO2010120649A2 Composition and use of n-alpha-methylhistamine dihydrochloride for the reduction of oxygen radical formation
10/21/2010WO2010120621A1 Hepatitis c virus inhibitors
10/21/2010WO2010120614A1 Benzodiazepine derivative for the treatment of hematopoietic neoplasm and leukemia
10/21/2010WO2010120599A2 Compositions and methods for treating cancer
10/21/2010WO2010120592A1 Combination therapy using an anti-egfr agent(s) and igf-1r specific inhibitors
10/21/2010WO2010120508A2 Regulation of mir-33 micrornas in the treatment of cholesterol-related disorders
10/21/2010WO2010120489A2 Drug delivery system and methods of use
10/21/2010WO2010120400A2 Substituted 4-amino-5-benzoyl-2-(phenylamino)thiophene-3-carbonitriles and substituted 4-amino-5-benzoyl-2-(phenylamino)thiophene-3-carboxamides as tubulin polymerization inhibitors
10/21/2010WO2010120389A2 Polymeric drug delivery systems and processes for producing such systems
10/21/2010WO2010120382A1 Compounds and methods for modulating activity of calcium release channels
10/21/2010WO2010120368A2 Stabilization of radiopharmaceutical compositions using ascorbic acid
10/21/2010WO2010120345A1 Metabolically inert antifolates: new indications and formulations
10/21/2010WO2010120337A1 Mitochondrial inhibitors to treat human disease
10/21/2010WO2010120336A1 High bioavailability oral picoplatin anti-cancer therapy
10/21/2010WO2010120332A1 Agents and methods to stimulate bone healing
10/21/2010WO2010120253A1 Thiocolchicoside and non-steroidal anti-inflammatory drug combinations
10/21/2010WO2010120237A1 Imidazole substituted pyrimidines useful in the treatment of glycogen synthase kinase 3 related disorders such as alzheimer's disease
10/21/2010WO2010120232A1 A prodrug comprising beta-keto carboxylic acid, beta-keto carboxylic acid salt or beta-keto carboxylic acid ester for drug delivery
10/21/2010WO2010120203A1 Use of organic dyes as analgesic agents
10/21/2010WO2010120195A1 Macrocyclic lactone combination compositions, vaccines and methods for producing same
10/21/2010WO2010120029A1 Composition comprising the extract of anemarrhena asphodeloides bunge or the compounds isolated from the same for preventing and treating lipid metabolism disorder
10/21/2010WO2010119990A1 Pharmaceutical compositions
10/21/2010WO2010119986A1 Method and composition for treating macular degeneration
10/21/2010WO2010119984A1 3-aryl or heteroaryl-substituted indole derivative
10/21/2010WO2010119966A1 Antiviral agent and cleanser
10/21/2010WO2010119955A1 Agent for preventing, inhibiting, or ameliorating skin aging due to buildup of advanced glycation end products
10/21/2010WO2010119942A1 Levocabastine suspension type eye lotion
1 ... 2036 2037 2038 2039 2040 2041 2042 2043 2044 2045 2046 2047 2048 2049 2050 2051 2052 2053 2054 2055 2056 ... 7860